Subscribe to RSS
DOI: 10.1055/a-2287-2919
Empfehlungen zum Lipidmanagement
Ein Expertenkonsens begleitend zum Leitdiagramm der Lipidakademie Baden-WürttembergRecommendations for Lipid ManagementAn Expert Consensus from Baden-WurttembergZusammenfassung
Trotz evidenzbasierter Leitlinienempfehlungen zum risikoadaptierten Lipidmanagement ist die Umsetzung dieser Empfehlungen in die klinische Routine nur unzureichend erfolgt. Der nachfolgende Expertenkonsensus soll dazu dienen, die Hintergründe und die Datenlage, die den Empfehlungen zugrunde liegen, zu erläutern sowie praktische Ratschläge für die notwendigen Laborparameter und deren Interpretation zu liefern. Dabei werden Limitationen der LDL-Cholesterin-Schätzung aufgeführt und Lösungsmöglichkeiten dargestellt. Die Empfehlungen geben auch Informationen zur Rationale eines beschleunigten Erreichens der LDL-Zielwerte nach einem akuten Koronarsyndrom und weisen auch auf die Notwendigkeit einer frühen Initiierung einer effektiven LDL-Cholesterin-Senkung bei Patienten mit einer familiären Hypercholesterinämie hin. Schließlich werden auch regulatorische Vorgaben im Lipidmanagement sowie die Erstattungs- und Verordnungsfähigkeit in Baden-Württemberg dargestellt.
Abstract
Despite evidence-based guideline recommendations on lipid management, implementation of lipid lowering therapies at prespecified LDL targets is poor in Germany. Therefore, the expert consensus document aims to provide background information on the rationale and appropriate use of lipid lowering therapies as well as to provide practical guidance on the panel of laboratory measures and their correct interpretation in the presence of relevant confounders. In particular, pitfalls regarding interpretation are highlighted and alternative options for correct interpretation are displayed. Moreover, the document addresses the particularities for accelerated lipid lowering for patients following an acute coronary syndrome as well as the need for early treatment initiation of effective LDL lowering therapies in patients with familial hypercholesterolemia. Finally, the document summarizes legal requirement by regulatory authorities for drug prescription and reimbursement in Baden Württemberg.
Schlüsselwörter
Primärprävention - Sekundärprävention - akutes Koronarsyndrom - Cholesterin - EskalationstherapieKeywords
primary prevention - secondary prevention - acute coronary syndrome - cholesterol - escalation therapyPublication History
Article published online:
31 July 2024
© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
Literatur
- 1 Mach F, Baigent C, Catapano AL. et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41: 111-188
- 2 Visseren FLJ, Mach F, Smulders YM. et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021; 42: 3227-3337
- 3 Leipziger Gesundheitsnetz. Behandlungspfad Fettstoffwechselstörungen. Zugriff am 13. Juni 2024 unter: https://www.gesundheitsnetz-leipzig.de/behandlungspfade/
- 4 Gouni-Berthold I, Schaper F, Schatz U. et al. Low-density lipoprotein cholesterol goal attainment in Germany: Results from the DA VINCI study. Atheroscler Plus 2022; 50: 10-16
- 5 Ray KK, Molemans B, Schoonen WM. et al. EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. Eur J Prev Cardiol 2021; 28: 1279-1289
- 6 Boekholdt SM, Hovingh GK, Mora S. et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol 2014; 64: 485-494
- 7 Johannesen CDL, Mortensen MB, Langsted A. et al. Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients. J Am Coll Cardiol 2021; 77: 1439-1450
- 8 Nordestgaard BG, Chapman MJ, Ray K. et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010; 31: 2844-2853
- 9 Nurmohamed NS, Kraaijenhof JM, Stroes ESG. Lp(a): a New Pathway to Target?. Curr Atheroscler Rep 2022; 24: 831-838
- 10 Krychtiuk KA, Ahrens I, Drexel H. et al. Acute LDL-C reduction post ACS: strike early and strike strong: from evidence to clinical practice. A clinical consensus statement of the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Association of Preventive Cardiology (EAPC) and the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. Eur Heart J Acute Cardiovasc Care 2022; 11: 939-949
- 11 Collet JP, Thiele H, Barbato E. et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2021; 42: 1289-1367
- 12 Hong SJ, Lee YJ, Lee SJ. et al. Treat-to-Target or High-Intensity Statin in Patients With Coronary Artery Disease: A Randomized Clinical Trial. JAMA 2023; 329: 1078-1087
- 13 Cholesterol Treatment Trialists Collaboration. Baigent C, Blackwell L, Emberson J. et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670-1681
- 14 Cannon CP, Blazing MA, Giugliano RP. et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med 2015; 372: 2387-2397
- 15 Sabatine MS, Giugliano RP, Keech AC. et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med 2017; 376: 1713-1722
- 16 Schwartz GG, Steg PG, Szarek M. et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med 2018; 379: 2097-2107
- 17 Nissen SE, Lincoff AM, Brennan D. et al. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. N Engl J Med 2023; 388: 1353-1364
- 18 Lipp H. Auswahl von Statinen vor dem Hintergrund neu verfasster Lipidleitlinien. Arzneimitteltherapie 2020; 38: 117-124
- 19 FDA. FDA Drug Safety Communication: New restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. Zugriff am 13. Juni 2024 unter: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-new-restrictions-contraindications-and-dose-limitations-zocor
- 20 Grundy SM, Cleeman JI, Merz CN. et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-239
- 21 Awad K, Serban MC, Penson P. et al. Effects of morning vs. evening statin administration on lipid profile: A systematic review and meta-analysis. J Clin Lipidol 2017; 11: 972-985.e9
- 22 Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 2005; 19: 117-125
- 23 Daiichi-Sankyo. Fachinformation Nilemdo 180 mg Filmtabletten. Oktober 2021. Zugriff am 13. Juni 2024 unter: https://www.nilemdo-nustendi.de/fileadmin/user_upload/Downloads_PDF/FI_Nilemdo_Filmtabletten_Oktober_2021.pdf
- 24 Ratiopharm. Fachinformation Simvastatin-ratiopharm® 10 mg/20 mg/40 mg/80 mg Filmtabletten. März 2023. Zugriff am 13. Juni 2024 unter: https://www.ratiopharm.de/assets/products/de/label/Simvastatin-ratiopharm 10 mg20 mg40 mg80 mg Filmtabletten - 8.pdf?pzn=895729
- 25 AbZ-Pharma. Fachinformation (August 2017) Atorvastatin AbZ 10 mg/20 mg/40 mg/80 mg. März 2023. Zugriff am 13. Juni 2024 unter: https://www.abz.de/assets/products/de/label/Atorvastatin AbZ 10 mg20 mg40 mg80 mg Filmtabletten - 9.pdf?pzn=9374966
- 26 AbZ-Pharma. Fachinformation Fluvastatin AbZ 20 mg/40 mg Hartkapseln. Juli 2018. Zugriff am 13. Juni 2024 unter: https://www.abz.de/assets/products/de/label/Fluvastatin AbZ 20 mg40 mg Hartkapseln - 3.pdf?pzn=6714315
- 27 Hersteller: Recordati Pharma GmbH. Fachinformation Livazo®. März 2021. Zugriff am 13. Juni 2024 im Internet: https://imedikament.de/livazo-2-mg-filmtabletten/fachinformation%23google_vignette
- 28 Ratiopharm. Fachinformation Lovastatin-ratiopharm® 20 mg/40 mg. August 2020. Zugriff am 13. Juni 2024 unter: https://www.ratiopharm.de/assets/products/de/label/Lovastatin-ratiopharm%20Tabletten%20-%203.pdf?pzn=187240
- 29 Fachinfo-Service. Fachinformation Pravastatin AbZ 20 mg/40 mg Tabletten. Januar 2024. Zugriff am 13. Juni 2024 unter: https://www.fachinfo.de/pdf/020417
- 30 Fachinfo-Service. Fachinformation Rosuvastatin-ratiopharm® Filmtabletten. Oktober 2023. Zugriff am 13. Juni 2024 unter: https://www.fachinfo.de/pdf/021796
- 31 Phan BA, Dayspring TD, Toth PP. Ezetimibe therapy: mechanism of action and clinical update. Vasc Health Risk Manag 2012; 8: 415-427
- 32 Organon. Fachinformation EZETROL® 10 mg Tabletten. Februar 2021. Zugriff am 13. Juni 2024 unter: https://www.organon.com/germany/wp-content/uploads/sites/38/2021/10/EZETROL-10-mg-Tabletten.pdf
- 33 Pinkosky SL, Newton RS, Day EA. et al. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun 2016; 7: 13457
- 34 Ballantyne CM, Banach M, Mancini GBJ. et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. Atherosclerosis 2018; 277: 195-203
- 35 Goldberg AC, Leiter LA, Stroes ESG. et al. Effect of Bempedoic Acid vs. Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial. JAMA 2019; 322: 1780-1788
- 36 Ballantyne CM, Laufs U, Ray KK. et al. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiol 2020; 27: 593-603
- 37 Robinson JG, Farnier M, Krempf M. et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1489-1499
- 38 Sabatine MS, Giugliano RP, Wiviott SD. et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1500-1509
- 39 Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S. et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet 2014; 383: 60-68
- 40 Wright RS, Ray KK, Raal FJ. et al. Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis. J Am Coll Cardiol 2021; 77: 1182-1193
- 41 Fachinfo-Service. Fachinformation Leqvio® 284 mg Injektionslösung in einer Fertigspritze. März 2022. Zugriff am 13. Juni 2024 unter: https://www.fachinfo.de/pdf/023202
- 42 Jacobson TA. NLA Task Force on Statin Safety – 2014 update. J Clin Lipidol 2014; 8: S1-S4
- 43 Finegold JA, Manisty CH, Goldacre B. et al. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice. Eur J Prev Cardiol 2014; 21: 464-474
- 44 Laufs U, Weingartner O, Kassner U. et al. [State of the Art: Statin Therapy]. Dtsch Med Wochenschr 2022; 147: 62-68
- 45 Marz W, Dippel FW, Theobald K. et al. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany. Atherosclerosis 2018; 268: 99-107
- 46 De Backer G, Jankowski P, Kotseva K. et al. Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis 2019; 285: 135-146
- 47 Gemeinsamer Bundesausschuss. Arzneimittel-Richtlinie. Zugriff am 13. Juni 2024 unter: https://www.g-ba.de/richtlinien/3/
- 48 Gemeinsamer Bundesausschuss. Arzneimittel-Richtlinie Anlage III: Übersicht über Verordnungseinschränkungen und -ausschlüsse. Zugriff am 13. Juni 2024 unter: https://www.g-ba.de/richtlinien/anlage/16/
- 49 Gemeinsamer Bundesausschuss. Arzneimittel-Richtlinie/Anlage III: Nummer 35a, Nummer 35b und Nummer 35c – Bempedoinsäure. Zugriff am 13. Juni 2024 unter: https://www.g-ba.de/beschluesse/5774/
- 50 KVBW. Arzneimittel-Richtwertvereinbarung 2023. Zugriff am 13. Juni 2024 unter: https://www.kvbawue.de/praxis/vertraege-recht/vertraege-von-a-z/arzneimittel
- 51 KVBW. Verordnungsforum 62 der Kassenärztlichen Vereinigung Baden-Württembergs. Zugriff am 13. Juni 2024 unter: https://www.kvbawue.de/presse/publikationen/verordnungsforum